Clinical Trials Browser

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

120 enrolled 8 charts

Dermatologic

Uveal Melanoma

NCT01229150 2017-05-23

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Phase 2 Completed

89 enrolled 28 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00553332 2016-04-22

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

29 enrolled 11 charts

Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular

NCT00936221 2016-03-14

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Phase 2 Completed

385 enrolled 11 charts

Dermatologic

Melanoma

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Phase 2 Unknown

164 enrolled

Breast

Triple Negative Breast Neoplasms

NCT00888134 2016-01-15

Selumetinib in Cancers With BRAF Mutations

Phase 2 Completed

28 enrolled 9 charts

Adult Solid Neoplasm

NCT01206140 2015-10-05

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

Phase 2 Completed

70 enrolled 8 charts

Sarcoma

NCT01085214 2015-08-19

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Phase 2 Completed

37 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT00866177 2015-08-11

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Completed

167 enrolled 6 charts

Dermatologic

Melanoma

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 2 Withdrawn

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT00338130 2014-08-13

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Phase 2 Completed

239 enrolled

Dermatologic

Melanoma

NCT00372788 2014-08-13

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Phase 2 Completed

88 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00372944 2014-08-13

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Phase 2 Completed

70 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00514761 2014-08-13

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

Phase 2 Completed

64 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Phase 2 Terminated

2 enrolled 9 charts

Dermatologic

Melanoma

NCT00604721 2014-05-28

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2 Completed

19 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

NF114

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

SEL-TH-1601

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

ORCHARD

SAFIR02_Breast

LS-NF1PNs

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

DOC-MEK

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

SAFIR02_Lung

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

PROTECT

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Personalized Treatment Selection for Metastatic Breast Cancer

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Selumetinib in Cancers With BRAF Mutations

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer